drugset / Trial / NCT00026208

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

NCT00026208

Phase 2 Completed 76 enrolled Stanford University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: This phase 2 trial is studying how well giving combination chemotherapy together with low-dose radiation therapy works in treating patients with stage I or stage IIA Hodgkin's lymphoma.

Timeline

Start
2001-06
Primary completion
2013-04-26
Completion
2017-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Bleomycin Unknown 5 unknown Intravenous
Subject Cyclophosphamide Other / unclassified 650 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Subject Etoposide Small molecule 60 mg/m2 Intravenous
Subject Prednisone Other / unclassified 40 mg/m2 Oral
Subject Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications